Protalix Biotherapeutics Inc Revenue Growth Rates (PLX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Protalix Biotherapeutics inc   (NYSEAMER: PLX)
 

PLX's Revenue Growth by Quarter and Year

Protalix Biotherapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PLX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 19.90
1st Quarter March 33.75
FY 53.65

PLXs Annual Revenue
Protalix Biotherapeutics Inc 's Revenue in the fiscal year 2025 $ 52.74 millions
Protalix Biotherapeutics Inc 's Revenue in the fiscal year 2024 $ 53.40 millions
Protalix Biotherapeutics Inc 's Revenue in the fiscal year 2023 $ 65.49 millions
Protalix Biotherapeutics Inc 's Revenue in the fiscal year 2022 $ 47.64 millions
Protalix Biotherapeutics Inc 's Revenue in the fiscal year 2021 $ 38.35 millions




PLX Revenue second quarter 2026 Y/Y Growth Comment
Protalix Biotherapeutics inc reported Revenue improvement of 27.05% year on year in the second quarter 2026, to $ 19.90 millions, this is lower than Protalix Biotherapeutics Inc 's recent average Revenue rise of 72.57%.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 36 other companies have achieved higher Revenue growth. While Protalix Biotherapeutics Inc ' s Revenue rise of 27.05% ranks overall at the positon no. 2200 in the second quarter 2026.


PLX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -49.95 % 73.69 % 21.69 %
3rd Quarter September - -0.61 % 73.53 % -27.01 %
2nd Quarter June 27.05 % 16.26 % -61.6 % 300.91 %
1st Quarter March 233.83 % 169.6 % -60.9 % -40.4 %
FY   - -1.24 % -18.49 % -

Financial Statements
Protalix Biotherapeutics Inc 's second quarter 2026 Revenue $ 19.90 millions PLX's Income Statement
Protalix Biotherapeutics Inc 's second quarter 2025 Revenue $ 15.66 millions Quarterly PLX's Income Statement


PLX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -48.91 % 1.45 % 1.35 %
3rd Quarter September - 13.98 % 33.33 % -70.5 %
2nd Quarter June -41.05 % 54.9 % 259.2 % 265.8 %
1st Quarter March 270.07 % -44.51 % -64.25 % 11.25 %
FY (Year on Year)   - -1.24 % -18.49 % -


Back to PLX Growth rate Comparisons >> Back to PLX Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #37
Healthcare Sector #324
Overall #2200

Revenue Y/Y Growth Statistics
High Average Low
1652.53 % 72.57 % -115.71 %
(Mar 31 2017)   (Sep 30 2016)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #37
Healthcare Sector #324
Overall #2200
Revenue Y/Y Growth Statistics
High Average Low
1652.53 % 72.57 % -115.71 %
(Mar 31 2017)   (Sep 30 2016)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Protalix Biotherapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
576.33 % 46.68 % -100 %
(Jun 30 2012)  


PLX's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Protalix Biotherapeutics Inc disclosed fall in Revenue from the first quarter by -41.05% to $ 19.90 millions, from $ 33.75 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 50 other companies have achieved higher Revenue quarter on quarter growth. While Protalix Biotherapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3598.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #51
Healthcare Sector #512
Overall #3598
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #51
Healthcare Sector #512
Overall #3598
Revenue Q/Q Growth Statistics
High Average Low
576.33 % 46.68 % -100 %
(Jun 30 2012)  


PLX's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Protalix Biotherapeutics Inc disclosed fall in Revenue from the first quarter by -41.05% to $ 19.90 millions, from $ 33.75 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 50 other companies have achieved higher Revenue quarter on quarter growth. While Protalix Biotherapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3598.


Protalix Biotherapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 80.62 $ 76.38 $ 52.74 $ 61.84 $ 61.95
Y / Y Revenue Growth (TTM) 30.14 % 27.8 % -1.23 % 35.42 % 62.79 %
Year on Year Revenue Growth Overall Ranking # 261 # 2138 # 2635 # 2218 # 2770
Seqeuential Revenue Change (TTM) 5.55 % 44.81 % -14.71 % -0.17 % 3.65 %
Seq. Revenue Growth (TTM) Overall Ranking # 2200 # 1152 # 648 # 469 # 3036


Cumulative Revenue growth Comment
Although Protalix Biotherapeutics Inc 's Annual Revenue growth year on year were below company's average 72.57% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 30.14% year on year, from 27.8% in Mar 31 2026.

In the Healthcare sector 72 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 261, from total ranking in previous quarter at 2138.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 37
Healthcare Sector # 73
Overall # 261

Revenue TTM Y/Y Growth Statistics
High Average Low
1652.53 %
 72.57 %
-115.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 37
Sector # 324
S&P 500 # 2200
Cumulative Revenue growth Comment
Although Protalix Biotherapeutics Inc 's Annual Revenue growth year on year were below company's average 72.57% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 30.14% year on year, from 27.8% in Mar 31 2026.

In the Healthcare sector 72 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 261, from total ranking in previous quarter at 2138.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 37
Healthcare Sector # 73
Overall # 261

Revenue TTM Y/Y Growth Statistics
High Average Low
1652.53 %
72.57 %
-115.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 37
Sector # 324
S&P 500 # 2200




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PLX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Rhythm Pharmaceuticals Inc 46.91%$ 46.911 millions
Axsome Therapeutics Inc 45.54%$ 45.543 millions
Guardant Health Inc 44.33%$ 44.332 millions
Omada Health Inc 43.27%$ 43.273 millions
Mannkind Corporation42.92%$ 42.922 millions
Butterfly Network Inc 42.47%$ 42.466 millions
Beta Bionics Inc 42.26%$ 42.261 millions
Vyne Therapeutics Inc 40.58%$ 40.580 millions
Qhslab Inc 39.98%$ 39.978 millions
Coherus Oncology inc 39.53%$ 39.526 millions
Neurocrine Biosciences Inc 39.49%$ 39.491 millions
Ss Innovations International Inc39.39%$ 39.393 millions
Assembly Biosciences Inc 38.94%$ 38.936 millions
Edap Tms Sa38.85%$ 38.847 millions
Picard Medical Inc 38.62%$ 38.620 millions
Hims and Hers Health Inc 38.41%$ 38.409 millions
Aquestive Therapeutics Inc 38.15%$ 38.149 millions
Mirum Pharmaceuticals Inc 37.92%$ 37.922 millions
Natera Inc 37.71%$ 37.715 millions
Zomedica Corp 36.59%$ 36.588 millions
Kura Oncology Inc 36.54%$ 36.538 millions
Scientific Industries Inc 36.02%$ 36.022 millions
Ceribell Inc 35.85%$ 35.852 millions
Intelligent Bio Solutions Inc 35.78%$ 35.777 millions
The Pennant Group Inc 35.76%$ 35.755 millions
Quanterix Corporation35.42%$ 35.416 millions
Inspiremd Inc 34.88%$ 34.882 millions
The Oncology Institute Inc 34.62%$ 34.624 millions
Agenus Inc34.36%$ 34.358 millions
Biodesix Inc 34.18%$ 34.184 millions


About Protalix Biotherapeutics Inc Revenue Growth Rates (PLX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Protalix Biotherapeutics Inc (CIK 1006281).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-094444
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Protalix Biotherapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.